NeSyDPP4-QSAR: A Neuro-Symbolic AI Approach for Potent DPP-4-Inhibitor Discovery in Diabetes Treatment
Hossain, D.; Chen, J. Y.
Show abstract
Diabetes Mellitus (DM) is a global epidemic and among the top ten leading causes of mortality (WHO, 2019), projected to rank seventh by 2030. The US National Diabetes Statistics Report (2021) states that 38.4 million Americans have diabetes. Dipeptidyl Peptidase-4 (DPP-4) is an FDA-approved target for type 2 diabetes mellitus (T2DM) treatment. However, current DPP-4 inhibitors are associated with adverse effects, including gastrointestinal issues, severe joint pain (FDA safety warning), nasopharyngitis, hypersensitivity, and nausea. Identifying novel inhibitors is crucial. Direct in vivo DPP-4 inhibition assessment is costly and impractical, making in silico IC50 prediction a viable alternative. Quantitative Structure-Activity Relationship (QSAR) modeling is a widely used computational approach for chemical substance assessment. We employ LTN, a neuro-symbolic approach, alongside DNN and transformers as baselines. DPP-4-related data is sourced from PubChem, ChEMBL, BindingDB, and GTP, comprising 6,563 bioactivity records (SMILES-based compounds with IC50 values) after deduplication and thresholding. A diverse set of features including descriptors (CDK Extended-PaDEL), fingerprints (Morgan), chemical language model embeddings (ChemBERTa2), LLaMa 3.2, and physicochemical properties is used to train the NeSyDPP4-QSAR model. The NeSyDPP4-QSAR model yielded the highest accuracy, incorporating CDKextended and Morgan fingerprints, with an accuracy of 0.9725, an F1-score of 0.9723, an ROC AUC of 0.9719, and an MCC of 0.9446. The performance was benchmarked against two standard baseline models: a deep neural network and a transformer. To ensure fair comparisons, DNN models used the equivalent attributes with the same dimension and network configuration as NeSyDPP4-QSAR. Our findings showed that integrating the Neuro-symbolic strategy (neural network-based learning and symbolic reasoning) holds immense potential for discovering drugs that can inhibit diabetes mellitus and classifying biological activities that inhibit it.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Improving prediction of drug-target interactions based on fusing multiple features with data balancing and feature selection techniques 97%
- PharmaNet: Pharmaceutical discovery with deep recurrent neural networks. 97%
- Antivirals for Monkeypox Virus: Proposing an Effective Machine/Deep Learning Framework 96%
Similar papers in this journal
- MACI: A machine learning-based approach to identify drug classes of antibiotic resistance genes from metagenomic data 96%
- Combining Multi-Dimensional Molecular Fingerprints to Predict hERG Cardiotoxicity of Compounds 96%
- AE-LGBM: Sequence-Based Novel Approach To Detect Interacting Protein Pairs via Ensemble of Autoencoder and LightGBM. 95%
Similar papers in this journal
- Pathway-guided deep neural network toward interpretable and predictive modeling of drug sensitivity 96%
- Advancements in Ligand-Based Virtual Screening through the Synergistic Integration of Graph Neural Networks and Expert-Crafted Descriptors 96%
- Retro Drug Design: From Target Properties to Molecular Structures 96%
Similar papers in this journal
- Interpretable and Generalizable Attention-Based Model for Predicting Drug-Target Interaction Using 3D Structure of Protein Binding Sites: SARS-CoV-2 Case Study and in-Lab Validation 96%
- AntiCP 2.0: An updated model for predicting anticancer peptides 96%
- Bioinfo-pharmacology: the example of therapeutic hypothermia 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.